Updated:
Debiopharm Innovation Fund
Debiopharm Innovation Fund is the corporate venture arm of Debiopharm Group focused on digital health and drug development technologies.
Debiopharm Innovation Fund
Debiopharm Innovation Fund was established in 2006 inside Debiopharm Group. The firm functions as the group's dedicated venture capital unit rather than a standalone asset manager. The strategy centers on early-stage venture investments in smart data technologies, digital health platforms, and patient digitisation tools. Capital is deployed through direct equity positions at seed and start-up stages. Geographic reach covers Europe and North America. No named portfolio holdings appear in available records. Team size and additional offices remain undisclosed. No dated operational events from the last 24 months are recorded. The structure ties investment decisions directly to Debiopharm Group's pharmaceutical operations, creating an internal sourcing and diligence channel that external venture firms lack.
General information
Firm type
Private Equity
Year founded
2006
AUM
150 (Altss estimate)
Location
Region
Europe
Country
Switzerland
City
Lausanne
Corporate office
Lausanne, Switzerland
Sector focus
Frequently asked questions
Who runs investment decisions at Debiopharm Innovation Fund?
Investment decisions sit inside Debiopharm Group with no external named principals disclosed in available records.
Does Debiopharm Innovation Fund participate in fund commitments or only direct deals?
The firm makes direct equity investments at seed and start-up stages.
What investment stages does Debiopharm Innovation Fund typically target?
The mandate covers seed and early-stage start-up rounds in venture.
Where does the underlying capital come from?
Capital originates from Debiopharm Group, the Swiss pharmaceutical company that established the fund in 2006.
Is Debiopharm Innovation Fund structured as a single family office or does it operate more like a venture firm?
It operates as the corporate venture capital arm of Debiopharm Group.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: